KALV
NASDAQKalVista Pharmaceuticals Inc.
Price$26.99+9.70 (+56.07%)
2026-03-092026-06-10
News · 26 weeks67+14%
2025-12-142026-06-07
Mix3990d
- Insider18(46%)
- Other12(31%)
- SEC Filings5(13%)
- Earnings2(5%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- PRChiesi Group Completes Acquisition of KalVista PharmaceuticalsPositioned to Expand Patient Access and Accelerate Impact in Rare Diseases Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. ("KalVista"). KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business unit, focused on research, development and commercialization of therapies for rare and ultra-rare conditions. With the completion of the transaction, Chiesi assumed ownership of EKTERLY® (sebetralstat), the first and only oral, on-demand treatment for hereditary angioedema (HAE) attacks in adults and adolescents ag
- SECSEC Form SCHEDULE 13G filed by KalVista Pharmaceuticals Inc.SCHEDULE 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by KalVista Pharmaceuticals Inc.SC 14D9/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
- INSIDERCHIEF DEVELOPMENT OFFICER Yea Christopher exercised 33,800 shares at a strike of $7.07 and sold $905,225 worth of shares (33,800 units at $26.78) (SEC Form 4)4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- PRKalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary AngioedemaPresentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). "These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them," said Ben Palleiko, Chief Executive Officer of KalVista. "Currently, the only FDA-appro
- INSIDERChief Commercial Officer Sweeny Nicole sold $39,872 worth of shares (1,489 units at $26.78) and converted options into 5,000 shares, increasing direct ownership by 6% to 59,291 units (SEC Form 4) to cover withholding tax4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Audhya Paul K. converted options into 5,000 shares and sold $59,955 worth of shares (2,239 units at $26.78), increasing direct ownership by 2% to 150,260 units (SEC Form 4) to satisfy tax liability4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 3,125 shares and sold $52,645 worth of shares (1,966 units at $26.78), increasing direct ownership by 0.51% to 229,918 units (SEC Form 4) (tax liability)4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 23,250 shares and sold $292,646 worth of shares (10,926 units at $26.78), increasing direct ownership by 3% to 479,989 units (SEC Form 4) (tax withholding)4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERChief Commercial Officer Sweeny Nicole converted options into 6,250 shares and sold $49,846 worth of shares (1,861 units at $26.78), increasing direct ownership by 9% to 55,780 units (SEC Form 4) to satisfy tax liability4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Yea Christopher sold $63,158 worth of shares (2,358 units at $26.78) and converted options into 3,750 shares, increasing direct ownership by 0.61% to 228,759 units (SEC Form 4) to satisfy withholding obligation4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Audhya Paul K. converted options into 6,250 shares and sold $71,916 worth of shares (2,685 units at $26.78), increasing direct ownership by 2% to 147,499 units (SEC Form 4) to cover withholding tax4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERChief Financial Officer Piekos Brian converted options into 5,000 shares and sold $39,882 worth of shares (1,489 units at $26.78), increasing direct ownership by 19% to 21,661 units (SEC Form 4) to cover withholding tax4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 1,774 shares and sold $29,650 worth of shares (1,108 units at $26.76), increasing direct ownership by 0.29% to 227,367 units (SEC Form 4) (tax liability)4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Audhya Paul K. converted options into 2,419 shares and sold $27,616 worth of shares (1,032 units at $26.76), increasing direct ownership by 0.97% to 143,934 units (SEC Form 4) (withholding obligation)4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 2,419 shares and sold $30,212 worth of shares (1,129 units at $26.76), increasing direct ownership by 0.28% to 467,665 units (SEC Form 4) to cover withholding tax4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- SECSEC Form 10-Q filed by KalVista Pharmaceuticals Inc.10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
- SECSEC Form SC 14D9 filed by KalVista Pharmaceuticals Inc.SC 14D9 - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
- INSIDERCHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 7,120 shares and sold $88,731 worth of shares (3,322 units at $26.71), increasing direct ownership by 0.82% to 466,375 units (SEC Form 4) to satisfy withholding obligation4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by KalVista Pharmaceuticals Inc.SCHEDULE 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
- ANALYSTKalVista Pharmaceuticals downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded KalVista Pharmaceuticals from Buy to Neutral and set a new price target of $27.00
- SECAmendment: SEC Form 10-KT/A filed by KalVista Pharmaceuticals Inc.10-KT/A - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
- SECSEC Form SC14D9C filed by KalVista Pharmaceuticals Inc.SC14D9C - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
- SECKalVista Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
- PRChiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease PortfolioHighlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn Acquisition adds to Chiesi's rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi's long-term commitment to people living with rare conditions Transaction expected to close in Q3 2026 Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the "Tran
KALV FAQ
7 questionsWhat does KalVista Pharmaceuticals Inc. do?
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE...Where does KALV stock trade?
KalVista Pharmaceuticals Inc. (KALV) is listed on NASDAQ.What sector and industry is KALV in?
KalVista Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did KalVista Pharmaceuticals Inc. go public?
KalVista Pharmaceuticals Inc. (KALV) completed its IPO in 2015.What are analysts saying about KALV?
KalVista Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $2700.00 price target on 2026-05-01. Recent price targets range from $1900.00 to $4800.00.What companies are similar to KALV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KALV side-by-side with any of them on Quantisnow.How can I track KALV on Quantisnow?
Quantisnow aggregates KalVista Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KALV to receive live email and push alerts on every new disclosure.